Abstract: A method of constitutively expressing a bacterial dinucleotide cyclase in a mammalian cell is provided. The method comprises transfecting the mammalian cell with a transgene encoding the bacterial dinucleotide cyclase and subjecting the mammalian cell to suitable growth conditions. In an embodiment, the bacterial dinucleotide cyclase is expressed in a tumour or cancer cell and is useful to treat cancer.

Abstract: A system and method for autonomous driving mode transition control based on driver detection is disclosed. A method of an example embodiment comprises: obtaining a status from a driver detection sensor in an autonomous vehicle; obtaining a current operational status of the autonomous vehicle and a current operational status of an autonomous driving system (ADS) within the autonomous vehicle; causing disengagement of the ADS in the autonomous vehicle upon detection of the presence of a driver in the autonomous vehicle and detection of a vehicle fault or ADS fault; and preventing disengagement of the ADS in the autonomous vehicle upon detection of the absence of a driver in the autonomous vehicle and detection of a vehicle fault or ADS fault.

Abstract: Herein is described oncolytic viruses for use as immunologic adjuvants. There is provided a method of adjuvanting an immune response to an antigenic protein in a mammalian subject by administering the oncolytic virus and at least one antigenic peptide, with the latter not encoded by the former. Without the requirement for the virus to encode the antigenic protein, therapies may be readily personalized or formulated. The virus may be attenuated or inactivated. Prime:boost therapies for tumours are also provided, in which the prime comprises at least one antigenic protein, the boost comprises a virus and at least one antigenic protein, the at least one antigenic protein of the prime and the at least one antigenic protein of the boost are based on the same at least one tumour associated antigen, and the at least one antigenic protein of the boost is not encoded by the virus of the boost.

Abstract: Embodiments of the invention include compositions and methods related to non-VSV rhabdoviruses and their use as anti-cancer therapeutics. Such rhabdoviruses possess tumor cell killing properties in vitro and in vivo.

Abstract: Embodiments disclosed herein include a first motor having a high gear ratio, a second motor having a low gear ratio, and a drive shaft, the first and second motors being connected to a load via the drift shaft. The motor system is arranged to at least one of electrically and mechanically disconnect the first motor when a speed of the first motor reaches a threshold speed such that the first motor does not act as a generator and consume mechanical power. In some embodiments, the first motor is a torque booster and the second motor is a high speed motor. The first motor may be electrically disconnected via one or more relays, couplers, and additional switching semiconductors. The first motor may be mechanically disconnected via a clutch.

Abstract: Herein is described oncolytic viruses for use as immunologic adjuvants. There is provided a method of adjuvanting an immune response to an antigenic protein in a mammalian subject by administering the oncolytic virus and at least one antigenic peptide, with the latter not encoded by the former. Without the requirement for the virus to encode the antigenic protein, therapies may be readily personalized or formulated. The virus may be attenuated or inactivated. Prime:boost therapies for tumours are also provided, in which the prime comprises at least one antigenic protein, the boost comprises a virus and at least one antigenic protein, the at least one antigenic protein of the prime and the at least one antigenic protein of the boost are based on the same at least one tumour associated antigen, and the at least one antigenic protein of the boost is not encoded by the virus of the boost.

Abstract: Certain embodiments are directed to viral production processes for the large scale production of vaccinia virus.

Abstract: A passenger transport system comprising at least one electromechanical self-powering RF signal generator having a push & return mechanism, and at least one passenger seat having a seat region, wherein said push & return mechanism is installed, said generator, which is provided with an RF transmitter, is equipped to self-generate electric power based on a mechanical force applied on the push & return mechanism by a passenger sitting in the seat region, and whereby said generated electric power is used for the RF transmitter to transmit an RF signal on an adjustable frequency in case the passenger sitting in the seat region thereby presses a switch of the push & return mechanism, and which passenger transport system further comprises: a central RF receiver for receiving transmitted RF signals which have features to identify the individual passenger seats he RF signals are transmitted from, and means for based on the received RF signals deriving information indicating which of the passenger seats

Abstract: The present invention relates to methods and compositions for use in inducing tumor-specific antibody mediated complement-dependent cytotoxic response in an animal having a tumor comprising administering to said animal a composition comprising a replication competent oncolytic virus wherein administration of the composition induces in the animal production of antibodies that mediate a CDC response specific to said tumor.

Abstract: Embodiments of the invention include compositions and methods related to replicative oncolytic rhabdoviruses pseudotyped with an arenavirus glycoprotein and their use as anti-cancer therapeutics particularly in combination with complement inhibitors.

Abstract: Certain embodiments are directed to viral production processes for the large scale production of vaccinia virus.

Abstract: The present invention pertains to a combination for simultaneous, separate or sequential use which comprises (a) an oncolytic virus and (b) a checkpoint inhibitor and to its use for the treatment of cancer.

Abstract: Certain embodiments are directed to viral production processes for the large scale production of vaccinia virus.

Abstract: The present invention pertains to a combination for simultaneous, separate or sequential use which comprises (a) an oncolytic virus and (b) a checkpoint inhibitor and to its use for the treatment of cancer.

Abstract: Embodiments of the invention include compositions and methods related to non-VSV rhabdoviruses and their use as anti-cancer therapeutics. Such rhabdoviruses possess tumor cell killing properties in vitro and in vivo.

Abstract: The present invention relates to methods and compositions for use in inducing tumor-specific antibody mediated complement-dependent cytotoxic response in an animal having a tumor comprising administering to said animal a composition comprising a replication competent oncolytic virus wherein administration of the composition induces in the animal production of antibodies that mediate a CDC response specific to said tumor.